Previous 10 | Next 10 |
Acorda Therapeutics, Inc. (ACOR) Q4 2018 Results Conference Call February 14, 2019 4:30 PM ET Company Participants Felicia Vonella – Executive Director-Investor Relations Ron Cohen – Chief Executive Officer Conference Call Participants Cory Kasimov – JP M...
The following slide deck was published by Acorda Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Acorda Therapeutics (NASDAQ: ACOR ) Q4 results ($M): Revenues: 69.2 (-63.3); Ampyra sales: 64.2 (-61.6%) due to generic competition. More news on: Acorda Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
Acorda Therapeutics, Inc. (NASDAQ:ACOR) today announced that Peter S. Carbone has joined the Company as Senior Vice President, Quality. Mr. Carbone will report to Ron Cohen, M.D., President and CEO of Acorda and will be a member of the Company’s Leadership Team. In his role, Mr. C...
NEW YORK, Feb. 01, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Rexnord Corporation (NYSE:RXN), Carlisle Companies Incorporated (NYSE:...
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its fourth quarter/year end 2018 update and financial results on Thursday, February 14 at 4:30 p.m. ET. To participate in the conference call, please dial (866) 393-4306 (domestic) o...
Photo Credit: Biomed Realty Recommendation I recommend long Acorda Therapeutics ( ACOR ) for 1-3 months aiming at a price target zone ranging from $20.23-$27.24 (currently trading at $15.95). The negative impact of generics erosion on Ampyra's sales has been overstated in my opinion,...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
InsiderInsights' Daily Round Up articles rate the "significance" of the top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the significance of an insider transaction, however, and there are many more "Signifi...
News, Short Squeeze, Breakout and More Instantly...
Acorda Therapeutics Inc. Company Name:
ACOR Stock Symbol:
NASDAQ Market:
Acorda Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 11.3% to $0.2025 on volume of 40,515,259 shares Rallybio Corporation (RLYB) rose 80.4% to $2.9401 on volume of 39,492,767 shares Trio Petroleum Corp. (TPET) rose 36.3% to $0.2499 on volume of 3...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) rose 28.8% to $0.0515 on volume of 62,068,605 shares Laser Photonics Corporation (LASE) rose 172.7% to $3.9 on volume of 54,588,758 shares WiSA Technologies Inc. (WISA) fell 6.1% to $0.0217 on volume of 2...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ("Nasdaq") today notified the Company that it will suspend trading in and delist the Company's common stock, effective with the opening of business on April 12, 2024. The notice follows the Company's April 1, 2024 announc...